January 11th 2025
Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia type 56, a particularly rare neurological disease.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Dyadic, Serum Institute of India Collaborate on Affordable and Accessible Antibodies
May 10th 2019Dyadic International has announced its collaboration agreement with Serum Institute of India for the development and manufacture of up to 12 antibodies and vaccines using Dyadic’s C1 gene expression system.